Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes

Area of Science:

• Cardiology
• Genetics
• Metabolic Disorders

Background:

• Autosomal recessive hypercholesterolemia (ARH) is a rare genetic lipid disorder.
• ARH significantly increases the risk of premature atherosclerotic cardiovascular disease (ASCVD).
• Limited data exist on clinical management and cardiovascular outcomes in ARH patients.

Purpose of the Study:

• To evaluate changes in lipid management strategies for ARH patients.
• To assess the achievement of low-density lipoprotein cholesterol (LDL-C) goals in ARH.
• To determine cardiovascular outcomes in ARH patients under intensive treatment.

Main Methods:

• A systematic electronic search identified published ARH cases.
• Follow-up data were collected from corresponding authors and treating physicians.
• A standardized protocol was used for data collection and analysis.

Main Results:

• 52 ARH patients (mean age 31.1 years) were analyzed with a mean follow-up of 14.1 years.
• Intensive treatments including statins, ezetimibe, apheresis, and lomitapide reduced LDL-C by 69.6% to a mean of 164.0 mg/dl.
• Despite treatment, 26.9% experienced ASCVD, and 11.5% developed aortic valve stenosis; age and baseline coronary artery disease predicted ASCVD.

Conclusions:

• Intensive treatments do not fully normalize LDL-C levels in ARH patients, leading to poor long-term cardiovascular prognosis.
• Early diagnosis and treatment are critical for managing ARH.
• An effective, standardized treatment protocol for ARH remains a significant unmet need.